GENetic and clinical predictors of treatment response in depression: The GenPod randomised trial protocol

Trials

Volumn 9, Issue , 2008, Pages

  Thomas, Laura ^a   Mulligan, Jean ^a   Mason, Victoria ^b   Tallon, Debbie ^a   Wiles, Nicola ^a   Cowen, Philip ^c   Nutt, David ^a   O'Donovan, Michael ^d   Sharp, Deborah ^a   Peters, Tim ^a   Lewis, Glyn ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF WORCESTER   (United Kingdom)

^c WARNEFORD HOSPITAL   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE; SEROTONIN; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; GENETIC POLYMORPHISM; HEALTH CARE COST; HUMAN; INDIVIDUALIZATION; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE REGRESSION; NATIONAL HEALTH SERVICE; OUTCOMES RESEARCH; PHARMACOGENETICS; PREDICTION; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT PLANNING;

EID: 45549098108     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-9-29     Document Type: Article

References (33)

1. Murray CJ Lopez AD Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study Lancet 1997, 349:1498-1504. 10.1016/S0140-6736(96)07492-2 9167458
2. NHS Health and Social Care Information Centre Prescription Cost Analysis Data Health Care Statistics 2006.
3. Health D NHS Executive Report: Burdens of Disease Leeds: Department of Health 1996.
4. Berndt ER Koran LM Finkelstein SN Gelenberg AJ Kornstein SG Miller IM Thase ME Trapp GA Keller MB Lost human capital from early-onset chronic depression Am J Psychiatry 2000, 157:940-947. 10.1176/appi.ajp.157.6.940 10831474
5. Murray CJ Lopez AD Jamison DT The global burden of disease in 1990: summary results, sensitivity analysis and future directions Bull World Health Organ 1994, 72:495-509. 8062404
6. Nemeroff CB Entsuah R Benattia I Demitrack M Sloan DM Thase ME Comprehensive Analysis of Remission (COMPARE) with Venlafaxine versus SSRIs Biol Psychiatry 2007.
7. Barbui C Hotopf M Amitriptyline v. the rest: Still the leading antidepressant after 40 years of randomised controlled trials Br J Psychiatry 2001, 178:129-144. 10.1192/bjp.178.2.129 11157426
8. Delgado PL Miller HL Salomon RM Licinio J Krystal JH Moreno FA Heninger GR Charney DS Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: Implications for the role of serotonin in the mechanism of antidepressant action Biol Psychiatry 1999, 46:212-220. 10.1016/S0006-3223(99)00014-1 10418696
9. Freemantle N Anderson IM Young P Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis B J Psych 2000, 177:292-302. 10.1192/ bjp.177.4.292 11116769
10. Lesch KP Bengel D Heils A Sabol SZ Greenberg BD Petri S Benjamin J Muller CR Hamer DH Murphy DL Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region Science 1996, 274:1527-1530. 10.1126/science.274.5292.1527 8929413
11. Laux G Konig W Lesch KP Stein A Intravenous versus oral treatment of endogenously depressed patients with doxepin - a double-blind study with plasma level determination. Wien-Med-Wochenschr 1989, 139(22):525-9. 2609672
12. Whale R Quested DJ Laver D Harrison PJ Cowen PJ Serotonin transporter (5-HTT) promoter genotype may influence the prolactin response to clomipramine Psychopharmacology 2000, 150:120-122. 10.1007/s002130000432 10867985
13. Smeraldi E Zanardi R Benedetti F Di Bella D Perez J Catalano M Polymorphism within the promoter of the serotonin transporter gene and the antidepressant efficacy of fluvoxamine Molecular Psychiatry 1998, 3:508-511. 10.1038/sj.mp.4000425 9857976
14. Pollock BG Ferrell RE Mulsant BH Mazumdar S Miller M Sweet RA Davis S Kirshner MA Houck PR Stack JA Reynolds CF Kupfer DJ Allelic variation in the serotonin transporter promotor affects onset of paroxetine treatment response in late-life depression Neuropsychopharmacology 2000, 23:587-590. 10.1016/S0893-133X(00)00132-9 11027924
15. Kim DK Lim SW Lee S Sohn SE Kim S Hahn CG Carroll BJ Serotonin transporter gene polymorphism and antidepressant response Genetics of Central Nervous System Diseases 2000, 11:215-219. 10683861
16. Hu XZ Rush AJ Charney D Wilson AF Sorant AJ Papanicolaou GJ Fava M Trivedi MH Wisniewski SR Laje G Paddock S McMahon FJ Manji H Lipsky RH Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression Arch Gen Psychiatry 2007, 64:783-792. 10.1001/ archpsyc.64.7.783 17606812
17. Massana J Moller HJ Burrows GD Montenegro RM Reboxetine: A double-blind comparison with fluoxetine in major depressive disorder International Clinical Psychopharmacology 1999, 14:73-80. 10.1097/ 00004850-199903000-00003 10220121
18. Venditti LN Arcelus A Birnbaum H Greenberg P Barr CE Rowland C Williamson T The impact of antidepressant use on social functioning: reboxetine versus fluoxetine International Clinical Psychopharmacology 2000, 15:279-289. 10993130
19. Lewis G Pelosi AJ Araya R Dunn G Measuring psychiatric disorder in the community: A standardised assessment for use by lay interviewers Psych Med 1992, 22:465-486.
20. Beck AT Ward CH Mendelsohn M Mock J Erbaugh J An inventory for measuring depression Arch Gen Psych 1961, 4:561-571.
21. Ware J Jr. Kosinski M Keller SD A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity Med Care 1996, 34:220-233. 10.1097/00005650-199603000-00003 8628042
22. Zigmond A Snaith R The hospital anxiety and depression scale Acta Psychiatrica Scandinavica 1983, 67:361-370. 10.1111/ j.1600-0447.1983.tb09716.x 6880820
23. Vanderkooy JD Kennedy SH Bagby RM Antidepressant side effects in depression patients treated in a naturalistic setting: A study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine Can J Psychiatry 2002, 47:174-180. 11926080
24. John OP Donahue EM Kentle RL The "Big Five " inventory - Version 4a and 54 Berkeley, Institute of Personality and Social Research, University of California, Berkeley 1991.
25. Moher D Schulz KF Altman DG The CONSORT statement: Revised recommendations for improving the quality of Reports of Parallel-Group randomized trial Lancet 2001, 357:1191-1194. 10.1016/ S0140-6736(00)04337-3 11323066
26. Lubin JH Gail MH On power and sample size for studying features of the relative odds of disease American Journal of Epidemiology 1990, 131:552-566. 2301364
27. Garcia-Closas M Lubin JH Power and sample size calculations in case-control studies of gene-environmental interactions: Comments on different approaches American Journal of Epidemiology 1999, 149:689-693. 10206617
28. Brookes ST Whitley E Egger M Davey Smith G Mulheran P Peters TJ Subgroup analyses in randomised controlled trials: Risks of sub-group specific analyses; power and sample size for the interaction test Journal of Clinical Epidemiology 2004, 57:229-236. 10.1016/j.jclinepi.2003.08.009 15066682
29. Brookes ST Whitley E Peters TJ Mulheran P Egger M Davey Smith G Subgroup analysis in randomised trials: Quantifying the risk of false-positives and false-negatives Health Technology Assessment 2001, 5:. 11701102
30. Kirov G Rees M Jones I MacCandless F Owen MJ Craddock N Bipolar disorder and the serotonin transporter gene: A family-based association study Psych Med 1999, 29:1249-1254. 10.1017/S003329179900882X 10576317
31. Ogilvie AD Battersby S Bubb VJ Fink G Harmer AJ Goodwin GM Smith CAD Polymorphism in the serotonin transporter gene associated with susceptibility to major depression Lancet 1996, 347:731-733. 10.1016/ S0140-6736(96)90079-3 8602004
32. Cuijpers P Minimal contact psychotherapy for depression (Protocol for a Cochrane Review) Oxford, Update Software 2 2001.
33. Roses AD Pharmacogenetics Human Molecular Genetics 2001, 10:2261-2267. 10.1093/hmg/10.20.2261 11673409